Data Sheet (Cat.No.T68147)

T-900607

Chemical Properties



CAS No. :	261944-52-9
Formula:	C14H10F5N3O4S
Molecular Weight:	411.3
Storage:	Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	T-900607 is a novel microtubule protein active agent that disrupts microtubule polymerization through a unique mechanism of action. t-900607 is cardiotoxic.
Targets(IC50)	Microtubule Associated
In vitro	t-900607 (compound 5 or VI) showed total growth inhibition for HeLa and MCF-7/ADR cells at<5 μM.[2]
In vivo	t-900607 (15 to 270 mg/m; administered intravenously; advanced and/or metastatic solid malignancies patients; over 30 minutes every 21 days) no DLTs were seen until 270 mg/m, the sixth dose level. The dose was decreased to 180 mg/m with increased cardiac monitoring and at this dose 3/4 of patients experienced cardiac toxicity. The study was reopened at 130 mg/m of 6 enrolled patients, 1 had grade 3 drug-related lethargy considered to be a DLT and this dose was considered the RP2D. No objective responses were seen but stable disease was reported on 7/20. The recommended phase II dose for t-900607 is 130 mg/m given as an intravenous infusion over 60 minutes on a 21-day cycle. Cardiac toxicity was seen with this schedule.[1]

Solubility Information

Solubility	DMSO: 4.12 mg/mL (10.02 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4313 mL	12.1566 mL	24.3132 mL
5 mM	0.4863 mL	2.4313 mL	4.8626 mL
10 mM	0.2431 mL	1.2157 mL	2.4313 mL
50 mM	0.0486 mL	0.2431 mL	0.4863 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gelmon KA, et al. A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130. Invest New Drugs. 2005;23 (5):445-453.

Houze, et al. Preparation of arylsulfonanilide ureas as antiproliferative agents. WO2000017159 A1.